November 30, 2017 09:24 AM EST
People
R&D

In re­or­ga­ni­za­tion, Jo­erg Moeller gath­ers all the phar­ma R&D reins at Bay­er as dis­cov­ery chief ex­its

John Carroll

Editor & Founder

Im­age: An­dreas Busch (left) and Jo­erg Moeller (right). Bay­er

An­dreas Busch, the head of dis­cov­ery at Bay­er, is ex­it­ing the com­pa­ny. And …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times